Exact Mass: 461.2279
Exact Mass Matches: 461.2279
Found 500 metabolites which its exact mass value is equals to given mass value 461.2279
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Pimozide
A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403) D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AG - Diphenylbutylpiperidine derivatives D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5.
Bitolterol
R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents
((2,6-Bis(1-methylethyl)phenoxy)sulfonyl)carbamic acid 2,6-bis(1-methylethyl)phenyl ester
plumbagine E alpha-D-xylopyranoside|plumbagoside B
Ala Asp Thr Arg
Arg Ser Ala Glu
pimozide
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AG - Diphenylbutylpiperidine derivatives D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; INTERNAL_ID 205; DATASET 20200303_ENTACT_RP_MIX501; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3862; ORIGINAL_PRECURSOR_SCAN_NO 3860 CONFIDENCE standard compound; INTERNAL_ID 205; DATASET 20200303_ENTACT_RP_MIX501; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3823; ORIGINAL_PRECURSOR_SCAN_NO 3820 CONFIDENCE standard compound; INTERNAL_ID 205; DATASET 20200303_ENTACT_RP_MIX501; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3854; ORIGINAL_PRECURSOR_SCAN_NO 3850 CONFIDENCE standard compound; INTERNAL_ID 205; DATASET 20200303_ENTACT_RP_MIX501; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8187; ORIGINAL_PRECURSOR_SCAN_NO 8184 CONFIDENCE standard compound; INTERNAL_ID 205; DATASET 20200303_ENTACT_RP_MIX501; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8258; ORIGINAL_PRECURSOR_SCAN_NO 8257 CONFIDENCE standard compound; INTERNAL_ID 205; DATASET 20200303_ENTACT_RP_MIX501; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8218; ORIGINAL_PRECURSOR_SCAN_NO 8216 CONFIDENCE standard compound; INTERNAL_ID 205; DATASET 20200303_ENTACT_RP_MIX501; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8255; ORIGINAL_PRECURSOR_SCAN_NO 8253 CONFIDENCE standard compound; INTERNAL_ID 205; DATASET 20200303_ENTACT_RP_MIX501; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8237; ORIGINAL_PRECURSOR_SCAN_NO 8235 CONFIDENCE standard compound; INTERNAL_ID 205; DATASET 20200303_ENTACT_RP_MIX501; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8257; ORIGINAL_PRECURSOR_SCAN_NO 8255 Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5.
Ala Cys Ile Arg
Ala Cys Leu Arg
Ala Cys Arg Ile
Ala Cys Arg Leu
Ala Asp Arg Thr
Ala Glu Arg Ser
Ala Glu Ser Arg
Ala Phe Pro Gln
Ala Phe Gln Pro
Ala Ile Cys Arg
Ala Ile Met Gln
Ala Ile Gln Met
Ala Ile Arg Cys
Ala Leu Cys Arg
Ala Leu Met Gln
Ala Leu Gln Met
Ala Leu Arg Cys
Ala Met Ile Gln
Ala Met Leu Gln
Ala Met Gln Ile
Ala Met Gln Leu
Ala Pro Phe Gln
Ala Pro Gln Phe
Ala Gln Phe Pro
Ala Gln Ile Met
Ala Gln Leu Met
Ala Gln Met Ile
Ala Gln Met Leu
Ala Gln Pro Phe
Ala Arg Cys Ile
Ala Arg Cys Leu
Ala Arg Asp Thr
Ala Arg Glu Ser
Ala Arg Ile Cys
Ala Arg Leu Cys
Ala Arg Ser Glu
Ala Arg Thr Asp
Ala Ser Glu Arg
Ala Ser Arg Glu
Ala Ser Val Trp
Ala Ser Trp Val
Ala Thr Asp Arg
Ala Thr Arg Asp
Ala Val Ser Trp
Ala Val Trp Ser
Ala Trp Ser Val
Ala Trp Val Ser
Cys Ala Ile Arg
Cys Ala Leu Arg
Cys Ala Arg Ile
Cys Ala Arg Leu
Cys Ile Ile Asn
Cys Ile Leu Asn
Cys Ile Asn Ile
Cys Ile Asn Leu
Cys Ile Gln Val
Cys Ile Val Gln
Cys Leu Ile Asn
Cys Leu Leu Asn
Cys Leu Asn Ile
Cys Leu Asn Leu
Cys Leu Gln Val
Cys Leu Val Gln
Cys Asn Ile Ile
Cys Asn Ile Leu
Cys Asn Leu Ile
Cys Asn Leu Leu
Cys Gln Ile Val
Cys Gln Leu Val
Cys Gln Val Ile
Cys Gln Val Leu
Cys Val Ile Gln
Cys Val Leu Gln
Cys Val Gln Ile
Cys Val Gln Leu
Asp Ala Arg Thr
Asp Ala Thr Arg
Asp Arg Ala Thr
Asp Arg Thr Ala
Asp Thr Ala Arg
Asp Thr Arg Ala
Glu Ala Arg Ser
Glu Ala Ser Arg
Glu Gly Arg Thr
Glu Gly Thr Arg
Glu Arg Ala Ser
Glu Arg Gly Thr
Glu Arg Ser Ala
Glu Arg Thr Gly
Glu Ser Ala Arg
Glu Ser Arg Ala
Glu Thr Gly Arg
Glu Thr Arg Gly
Phe Ala Pro Gln
Phe Ala Gln Pro
Phe Pro Ala Gln
Phe Pro Gln Ala
Phe Gln Ala Pro
Phe Gln Pro Ala
Gly Glu Arg Thr
Gly Glu Thr Arg
Gly Ile Ser Trp
Gly Ile Trp Ser
Gly Leu Ser Trp
Gly Leu Trp Ser
Gly Arg Glu Thr
Gly Arg Thr Glu
Gly Ser Ile Trp
Gly Ser Leu Trp
Gly Ser Trp Ile
Gly Ser Trp Leu
Gly Thr Glu Arg
Gly Thr Arg Glu
Gly Thr Val Trp
Gly Thr Trp Val
Gly Val Thr Trp
Gly Val Trp Thr
Gly Trp Ile Ser
Gly Trp Leu Ser
Gly Trp Ser Ile
Gly Trp Ser Leu
Gly Trp Thr Val
Gly Trp Val Thr
Ile Ala Met Gln
Ile Ala Gln Met
Ile Cys Ile Asn
Ile Cys Leu Asn
Ile Cys Asn Ile
Ile Cys Asn Leu
Ile Cys Gln Val
Ile Cys Val Gln
Ile Gly Ser Trp
Ile Gly Trp Ser
Ile Ile Cys Asn
Ile Ile Asn Cys
Ile Leu Cys Asn
Ile Leu Asn Cys
Ile Met Ala Gln
Ile Met Gln Ala
Ile Asn Cys Ile
Ile Asn Cys Leu
Ile Asn Ile Cys
Ile Asn Leu Cys
Ile Gln Ala Met
Ile Gln Cys Val
Ile Gln Met Ala
Ile Gln Val Cys
Ile Ser Gly Trp
Ile Ser Trp Gly
Ile Val Cys Gln
Ile Val Gln Cys
Ile Trp Gly Ser
Ile Trp Ser Gly
Lys Met Pro Ser
Lys Met Ser Pro
Lys Asn Asn Ser
Lys Asn Ser Asn
Lys Pro Met Ser
Lys Pro Ser Met
Lys Ser Met Pro
Lys Ser Asn Asn
Lys Ser Pro Met
Leu Ala Met Gln
Leu Ala Gln Met
Leu Cys Ile Asn
Leu Cys Leu Asn
Leu Cys Asn Ile
Leu Cys Asn Leu
Leu Cys Gln Val
Leu Cys Val Gln
Leu Gly Ser Trp
Leu Gly Trp Ser
Leu Ile Cys Asn
Leu Ile Asn Cys
Leu Leu Cys Asn
Leu Leu Asn Cys
Leu Met Ala Gln
Leu Met Gln Ala
Leu Asn Cys Ile
Leu Asn Cys Leu
Leu Asn Ile Cys
Leu Asn Leu Cys
Leu Gln Ala Met
Leu Gln Cys Val
Leu Gln Met Ala
Leu Gln Val Cys
Leu Ser Gly Trp
Leu Ser Trp Gly
Leu Val Cys Gln
Leu Val Gln Cys
Leu Trp Gly Ser
Leu Trp Ser Gly
Met Ala Ile Gln
Met Ala Leu Gln
Met Ala Gln Ile
Met Ala Gln Leu
Met Ile Ala Gln
Met Ile Gln Ala
Met Lys Pro Ser
Met Lys Ser Pro
Met Leu Ala Gln
Met Leu Gln Ala
Met Asn Val Val
Met Pro Lys Ser
Met Pro Ser Lys
Met Gln Ala Ile
Met Gln Ala Leu
Met Gln Ile Ala
Met Gln Leu Ala
Met Ser Lys Pro
Met Ser Pro Lys
Met Val Asn Val
Met Val Val Asn
Asn Cys Ile Ile
Asn Cys Ile Leu
Asn Cys Leu Ile
Asn Cys Leu Leu
Asn Ile Cys Ile
Asn Ile Cys Leu
Asn Ile Ile Cys
Asn Ile Leu Cys
Asn Lys Asn Ser
Asn Lys Ser Asn
Asn Leu Cys Ile
Asn Leu Cys Leu
Asn Leu Ile Cys
Asn Leu Leu Cys
Asn Met Val Val
Asn Asn Lys Ser
Asn Asn Ser Lys
Asn Ser Lys Asn
Asn Ser Asn Lys
Asn Val Met Val
Asn Val Val Met
Pro Ala Phe Gln
Pro Ala Gln Phe
Pro Phe Ala Gln
Pro Phe Gln Ala
Pro Lys Met Ser
Pro Lys Ser Met
Pro Met Lys Ser
Pro Met Ser Lys
Pro Gln Ala Phe
Pro Gln Phe Ala
Pro Ser Lys Met
Pro Ser Met Lys
Gln Ala Phe Pro
Gln Ala Ile Met
Gln Ala Leu Met
Gln Ala Met Ile
Gln Ala Met Leu
Gln Ala Pro Phe
Gln Cys Ile Val
Gln Cys Leu Val
Gln Cys Val Ile
Gln Cys Val Leu
Gln Phe Ala Pro
Gln Phe Pro Ala
Gln Ile Ala Met
Gln Ile Cys Val
Gln Ile Met Ala
Gln Ile Val Cys
Gln Leu Ala Met
Gln Leu Cys Val
Gln Leu Met Ala
Gln Leu Val Cys
Gln Met Ala Ile
Gln Met Ala Leu
Gln Met Ile Ala
Gln Met Leu Ala
Gln Pro Ala Phe
Gln Pro Phe Ala
Gln Val Cys Ile
Gln Val Cys Leu
Gln Val Ile Cys
Gln Val Leu Cys
Arg Ala Asp Thr
Arg Ala Glu Ser
Arg Ala Ser Glu
Arg Ala Thr Asp
Arg Asp Ala Thr
Arg Asp Thr Ala
Arg Glu Ala Ser
Arg Glu Gly Thr
Arg Glu Ser Ala
Arg Glu Thr Gly
Arg Gly Glu Thr
Arg Gly Thr Glu
Arg Ser Glu Ala
Arg Thr Ala Asp
Arg Thr Asp Ala
Arg Thr Glu Gly
Arg Thr Gly Glu
Ser Ala Glu Arg
Ser Ala Arg Glu
Ser Ala Val Trp
Ser Ala Trp Val
Ser Glu Ala Arg
Ser Glu Arg Ala
Ser Gly Ile Trp
Ser Gly Leu Trp
Ser Gly Trp Ile
Ser Gly Trp Leu
Ser Ile Gly Trp
Ser Ile Trp Gly
Ser Lys Met Pro
Ser Lys Asn Asn
Ser Lys Pro Met
Ser Leu Gly Trp
Ser Leu Trp Gly
Ser Met Lys Pro
Ser Met Pro Lys
Ser Asn Lys Asn
Ser Asn Asn Lys
Ser Pro Lys Met
Ser Pro Met Lys
Ser Arg Ala Glu
Ser Arg Glu Ala
Ser Val Ala Trp
Ser Val Trp Ala
Ser Trp Ala Val
Ser Trp Gly Ile
Ser Trp Gly Leu
Ser Trp Ile Gly
Ser Trp Leu Gly
Ser Trp Val Ala
Thr Ala Asp Arg
Thr Ala Arg Asp
Thr Asp Ala Arg
Thr Asp Arg Ala
Thr Glu Gly Arg
Thr Glu Arg Gly
Thr Gly Glu Arg
Thr Gly Arg Glu
Thr Gly Val Trp
Thr Gly Trp Val
Thr Arg Ala Asp
Thr Arg Asp Ala
Thr Arg Glu Gly
Thr Arg Gly Glu
Thr Val Gly Trp
Thr Val Trp Gly
Thr Trp Gly Val
Thr Trp Val Gly
Val Ala Ser Trp
Val Ala Trp Ser
Val Cys Ile Gln
Val Cys Leu Gln
Val Cys Gln Ile
Val Cys Gln Leu
Val Gly Thr Trp
Val Gly Trp Thr
Val Ile Cys Gln
Val Ile Gln Cys
Val Leu Cys Gln
Val Leu Gln Cys
Val Met Asn Val
Val Met Val Asn
Val Asn Met Val
Val Asn Val Met
Val Gln Cys Ile
Val Gln Cys Leu
Val Gln Ile Cys
Val Gln Leu Cys
Val Ser Ala Trp
Val Ser Trp Ala
Val Thr Gly Trp
Val Thr Trp Gly
Val Val Met Asn
Val Val Asn Met
Val Trp Ala Ser
Val Trp Gly Thr
Val Trp Ser Ala
Val Trp Thr Gly
Trp Ala Ser Val
Trp Ala Val Ser
Trp Gly Ile Ser
Trp Gly Leu Ser
Trp Gly Ser Ile
Trp Gly Ser Leu
Trp Gly Thr Val
Trp Gly Val Thr
Trp Ile Gly Ser
Trp Ile Ser Gly
Trp Leu Gly Ser
Trp Leu Ser Gly
Trp Ser Ala Val
Trp Ser Gly Ile
Trp Ser Gly Leu
Trp Ser Ile Gly
Trp Ser Leu Gly
Trp Ser Val Ala
Trp Thr Gly Val
Trp Thr Val Gly
Trp Val Ala Ser
Trp Val Gly Thr
Trp Val Ser Ala
Trp Val Thr Gly
Dasolampanel etibutil
C78272 - Agent Affecting Nervous System > C47795 - CNS Stimulant
(9R)-9-[[3,6-Dideoxy-4-O-(1H-indol-3-ylcarbonyl)-alpha-L-arabino-hexopyranosyl]oxy]decanoic acid
10-[[3,6-Dideoxy-4-O-(1H-indol-3-ylcarbonyl)-alpha-L-arabino-hexopyranosyl]oxy]decanoic acid
(2S)-2-amino-N-(2,6-dimethylphenyl)-N-(3-pyridin-3-ylpropyl)propanamide;(2R,3R)-2,3-dihydroxybutanedioic acid
4-[4-[(6S,7R,8R)-4-(2-cyclopropyl-1-oxoethyl)-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]-N,N-dimethylbenzamide
(6R,7R,8R)-7-[4-(1-cyclohexenyl)phenyl]-8-(hydroxymethyl)-N-(3-methoxyphenyl)-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7S,8S)-7-[4-(1-cyclohexenyl)phenyl]-8-(hydroxymethyl)-N-(3-methoxyphenyl)-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
cyclopropyl-[(1S)-1-(hydroxymethyl)-7-methoxy-1-[(3-methoxyphenyl)methyl]-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanone
4-[4-[(6R,7R,8S)-4-(2-cyclopropyl-1-oxoethyl)-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]-N,N-dimethylbenzamide
3-[4-[(6S,7S,8R)-4-[cyclobutyl(oxo)methyl]-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]-N,N-dimethylbenzamide
3-[4-[(6S,7R,8R)-4-[cyclobutyl(oxo)methyl]-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]-N,N-dimethylbenzamide
(6R,7R,8S)-7-[4-(1-cyclohexenyl)phenyl]-8-(hydroxymethyl)-N-(3-methoxyphenyl)-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7S,8R)-7-[4-(1-cyclohexenyl)phenyl]-8-(hydroxymethyl)-N-(3-methoxyphenyl)-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
[(1R)-1-(cyclopentylmethyl)-7-methoxy-2-methylsulfonyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
[(1S)-1-(cyclopentylmethyl)-7-methoxy-2-methylsulfonyl-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]yl]methanol
cyclopropyl-[(1R)-1-(hydroxymethyl)-7-methoxy-1-[(3-methoxyphenyl)methyl]-2-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanone
4-[4-[(6S,7S,8S)-4-(2-cyclopropyl-1-oxoethyl)-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]-N,N-dimethylbenzamide
4-[4-[(6S,7S,8R)-4-(2-cyclopropyl-1-oxoethyl)-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]-N,N-dimethylbenzamide
4-[4-[(6R,7S,8S)-4-(2-cyclopropyl-1-oxoethyl)-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]-N,N-dimethylbenzamide
4-[4-[(6R,7R,8R)-4-(2-cyclopropyl-1-oxoethyl)-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]-N,N-dimethylbenzamide
3-[4-[(6R,7S,8S)-4-[cyclobutyl(oxo)methyl]-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]-N,N-dimethylbenzamide
3-[4-[(6R,7R,8S)-4-[cyclobutyl(oxo)methyl]-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]-N,N-dimethylbenzamide
3-[4-[(6R,7S,8R)-4-[cyclobutyl(oxo)methyl]-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]-N,N-dimethylbenzamide
3-[4-[(6R,7R,8R)-4-[cyclobutyl(oxo)methyl]-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octan-7-yl]phenyl]-N,N-dimethylbenzamide
Bitolterol
R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03A - Adrenergics, inhalants > R03AC - Selective beta-2-adrenoreceptor agonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent > C319 - Bronchodilator C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents